MedTrace Logo

Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients

NCT05821478 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-07-09

No results posted yet for this study

Summary

The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative

Conditions

Interventions

DRUG

ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy

a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin

DRUG

Lymecyclin and corresponding placebos of the experimental arm

12-week course of oral lymecycline.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Caen

    collaborator OTHER

  • Hôpital Necker-Enfants Malades

    collaborator OTHER

  • Ministry of Health, France

    collaborator OTHER_GOV

  • Assistance Publique Hopitaux De Marseille

    collaborator OTHER

  • Institut Pasteur

    lead INDUSTRY

Principal Investigators

  • Maïa Delage-Toriel, MD · Institut Pasteur

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-22
Primary Completion
2027-02-28
Completion
2028-02-27

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05821478 on ClinicalTrials.gov